Market Overview

Morgan Stanley Expects Theravance to Continue to Underperform Following 4Q Earnings

Related THRX
Theravance Inc Reports Prelim Tender Offer Results
Glaxosmithkline, Theravance Intend to File Relvar Ellipta for COPD in Japan

In a report published Friday, Morgan Stanley analyst David Friedman reiterated an Underweight rating and $13.00 price target on Theravance (NASDAQ: THRX).

In the report, Morgan Stanley noted, “THRX is still planning for a split by 1Q14. While we await details on the ultimate capital structure and tax rate of the Royalty Co., which is remaining in California, we note that our model currently assumes minimal OpEx and no taxes ever being paid (based on NOL use).”

Theravance closed on Thursday at $36.13.

Latest Ratings for THRX

May 2015Cowen & Co.DowngradesMarket Perform
Jul 2014Bank of AmericaDowngradesBuyNeutral
Jun 2014StifelDowngradesBuyHold

View More Analyst Ratings for THRX
View the Latest Analyst Ratings

Posted-In: David Friedman Morgan StanleyAnalyst Color Reiteration Analyst Ratings


Related Articles (THRX)

View Comments and Join the Discussion!